Introducing a noninvasive, non-surgical, and reversible animal model for fecal incontinence using abobotulinumtoxinA in dogs.

In contrast, there were highly significant decreases in amplitude after treatment with abobotulinumtoxinA-both in 2-week period after injection and 6-weeks period after injection-in comparison with no treatment (amplitudes were 1,062.03 ± 91.50 μV before receiving any treatment, 876.47 ± 102.66 μV one day after abobotulinumtoxinA injection, 339.86 ± 103.11 μV one week after abobotulinumtoxinA injection, 391.05 ± 44.41 μV two weeks after abo-botulinumtoxinA injection, and 145.25 ± 45.96 μV four weeks after abobotulinumtoxinA injection; p < 0.05).

also in 132,142 other papers